Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Quantitative MYD88L265P and CXCR4S338X analysis in blood and marrow by digital droplet PCR or cell-free DNA may contribute to better assessment of trial outcomes vs serum IgM level changes in Waldenstrom macroglobulinemia.”
Title: Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom Macroglobulinemia
Authors: Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Maria Luisa Guerrera, Alberto Guijosa, Hao Sun, John M Hatcher, Abigail Peachey, Christopher J Patterson, Kirsten E. Meid, Joshua Gustine, Andrew R. Branagan, Shayna Sarosiek, Jorge J. Castillo, Steven P. Treon
You can read the Full Article in Blood Advances.
You can find more posts featuring Robert Orlowski on OncoDaily.
